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Cardiac hypertrophy results from increased mechanical load on the heart and through
the actions of local and systemic neuro-humoral factors, cytokines and growth factors.
These mechanical and neuroendocrine effectors act through stretch, G protein–coupled
receptors and tyrosine kinases to induce the activation of a myriad of intracellular signaling
pathways including the extracellular signal-regulated kinases 1/2 (ERK1/2). Since most
stimuli that provoke myocardial hypertrophy also elicit an acute phosphorylation of
the threonine-glutamate-tyrosine (TEY) motif within the activation loops of ERK1 and
ERK2 kinases, resulting in their activation, ERKs have long been considered promotors
of cardiac hypertrophy. Several mouse models were generated in order to directly
understand the causal role of ERK1/2 activation in the heart. These models include
direct manipulation of ERK1/2 such as overexpression, mutagenesis or knockout
models, manipulations of upstream kinases such as MEK1 and manipulations of
the phosphatases that dephosphorylate ERK1/2 such as DUSP6. The emerging
understanding from these studies, as will be discussed here, is more complex than
originally considered. While there is little doubt that ERK1/2 activation or the lack of it
modulates the hypertrophic process or the type of hypertrophy that develops, it appears
that not all ERK1/2 activation events are the same. While much has been learned, some
questions remain regarding the exact role of ERK1/2 in the heart, the upstream events
that result in ERK1/2 activation and the downstream effector in hypertrophy.
Keywords: extracellular signal-regulated kinases, mitogen activated protein kinase, cardiac hypertrophy, mouse
models, signaling
Cardiac Hypertrophy
Countless studies have shown that cardiac hypertrophy is independently associatedwith an increased
risk for heart failure and life threatening arrhythmias. Even with modern treatment the presence of
left ventricular hypertrophy in hypertensive patients is associated with a 2.8-fold greater risk for
ventricular tachycardia or fibrillation (Chatterjee et al., 2014).
Work overload results in structural remodeling of the heart and in a variety of functional changes
(Kehat and Molkentin, 2010b). Pressure overload, such that occurs in patients with hypertension
or stenosis of the aortic valve, causes an increase in ventricular mass with a high absolute or
relative wall thickness. In these patients both systolic and diastolic ventricular wall stresses are
usually normal because concentric hypertrophy counterbalance the effect of elevated systolic and
diastolic pressures (Grossman and Paulus, 2013). However, the compensatory increase in ventricular
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thickness eventually leads to diastolic dysfunction and diastolic
heart failure (Gaasch and Zile, 2011).
Eccentric hypertrophy is the result of volume rather than
pressure overload on the heart. A typical cause of volume-
overload is mitral valve regurgitation, which increases the
diastolic volume but not the systolic pressure in the heart.
In the initial compensated phase, this hypertrophy corrects
systolic ventricular wall stress but fail to normalize diastolic
ventricular wall stress (Grossman and Paulus, 2013). Over time
the progressive ventricular dilatation grows out of proportion to
the myocardial mass, and systolic function deteriorates.
The heart may also undergo growth in response to high-
intensity exercise training, termed physiological cardiac
hypertrophy. This physiological cardiac hypertrophy is associated
with normal or enhanced cardiac function and mostly does
not have adverse consequences (Weeks and McMullen, 2011),
however, there may be a threshold above which exercise training
may also increase the risk of arrhythmias or sudden cardiac death
(La Gerche and Prior, 2007). Although eccentric hypertrophy
initially resembles physiological growth, and there might be
some overlap between these phenomena, its effect on diastolic
wall stress and eventual deterioration in function, suggests that
maladaptive hypertrophy develops insidiously during volume
overload. Patients with systolic heart failure and reduced ejection
fraction often, but not always, exhibit ventricular dilatation with
eccentric hypertrophy (Gaasch et al., 2008).
At the cardiomyocyte level, cardiac hypertrophy is initiated
by alterations in the cell’s architecture and morphology, and
cardiomyocytes are able to grow in size through the synthesis
and depositions of new sarcomers. Concentric growth elicits a
parallel deposition of new sarcomeric units, resulting in transverse
growth of the myocytes. In contrast, chronic volume-overload
initiates the addition of sarcomeres in series, resulting in a relative
increase in cardiomyocyte length. Both experimental evidence
and modeling show excellent agreement between changes at the
sarcomere, cardiomyocyte, and the whole heart levels (Goktepe
et al., 2010). We still do not know precisely how individual
myocytes sense the forces imposed by pressure or volumeoverload
and how they are translated in the cell into sarcomerogenesis that
results in cell thickening, lengthening, or both. It is also obvious
that many functional changes occur in the cardiomyocytes in
addition to the structural ones (Kehat andMolkentin, 2010b). The
relative importance of the alterations in structure versus change in
function is also still unknown.
Mitogen Activated Protein Kinase (MAPK)
Pathway
The mitogen activated protein kinase (MAPK) pathway is a
signaling pathway comprised of sequentially acting protein
kinases that participate in regulation of cell growth, proliferation,
differentiation, survival, transformation, apoptosis and other
processes (Shaul and Seger, 2007).
Transmission of signals through this pathway is usually
initiated by G protein–coupled receptor, receptor tyrosine kinas
or by stress stimuli, and is then carried on by activated small G-
proteins, which trigger a cascade of phosphorylation reactions
that culminate in the dual phosphorylation and activation of
terminal MAPK. These MAPK cascades consist of at least three
tiers which constitute the main pathway: MAPK kinase kinase
(MAP3K), MAPK kinase (MAP2K), and a MAPK. One or more
of the kinase components in each level phosphorylate and activate
components in the next level ending with the activation of
downstream regulatory proteins by MAPKs and the initiation of
the required physiologic effect.
Three main branches of the MAPK signaling pathway have
been described and named for their terminal component
(MAPK): Extracellular signal-regulated kinases (ERK) 1/2, p38
kinases, and c-Jun N-terminal kinases (JNKs). Human ERK1 and
ERK2 have 84% identity in sequence and are believed to share
most if not all functions. ERK1 contains additional 17 amino
acid addition to the N-terminal domain. Collectively these two
proteins (ERK1 and ERK2) are referred to as ERK1/2.
Additional MAP kinases which are not specified to any known
pathway have been identified including ERK5, ERK3/4, and
ERK8. For each branch, the MAPK component is specifically
activated by a distinct MAP2K: MEK1/2 for ERK1/2, MKK3/6
for p38, and MKK4/7 for JNKs. The MAP2K can be activated by
more than one MAP3K and it is presumed that this activation
is influenced by the type of stimuli. For example, activation of
ERK1/2 in response to growth hormone stimulation begins with
theMAP3K c-RAF, although pro-inflammatory stimulation could
induce activation of ERK1/2 via different MAP3K.
Generally, activation of JNK and p38 kinases is associatedmore
with pro-inflammatory and stress induced signal transduction
as opposed to ERK1/2 activation which tends to have greater
influence on cell growth and proliferation. Specifically, the p38
cascade regulates angiogenesis, cell proliferation, inflammation
and production of cytokines and the JNK cascade plays a role in
apoptosis and development of cellular immune system, whereas
ERK1/2 are more involved in regulation of meiosis, mitosis and
post-mitotic function.
In cardiac myocyte, ERK signaling cascade is classically
initiated at the cell membrane by activation of the small G
protein Ras, leading to the recruitment and activation of MAP3K,
c-RAF (Wellbrock et al., 2004). Downstream of c-RAF are
MAPK/ERK kinase (MEK) 1/2 dual-specificity protein kinases
which are exclusive activators of ERK1/2 (Figure 1). MEK1/2
directly activates ERK1/2 by phosphorylating the threonine-
glutamate-tyrosine (TEY) motif located within their activation
loops (Shaul and Seger, 2007). Activation of ERK1/2 leads to
the phosphorylation of numerous cytoplasmic targets and also
to the translocation of ERK into the nucleus and activation
of transcription factors such as Elk-1, c-FOS, p53, GATA4,
and Ets1/2, which are important regulators of growth and
proliferation.
The duration, extent, and subcellular compartment of ERK1/2
activation are important for ERK biological effects. Inactivation
of ERK1/2 is mediated mainly by phosphatases such as protein
phosphatase 2A (PP2A) or dual-specificity phosphatases (DUSPs)
which dephosphorylate either or both regulatory tyrosine and
threonine residues in the activation loop (Fjeld et al., 2000). Of the
different Dusp genes, five have been reported to prefer p38 and
JNK over ERK1/2, including DUSP1, DUSP4, DUSP8, DUSP10,
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FIGURE 1 | ERK signaling cascade is classically initiated at the cell
membrane, leading to the recruitment and activation of MAP3K, c-RAF.
Downstream of c-RAF are MAPK/ERK kinase (MEK) 1/2 dual-specificity protein
kinases which directly activate ERK1/2 by phosphorylation. Gain-of-function
approaches included over-expression of a constitutive active MEK1 in the heart,
knockout of the phosphatase DUSP6, or overexpression of an ERK2 with a
phosphomimetic mutation Threonin 188 to aspartate. Loss of function
approaches for ERK included partial or complete knockout of ERK1 and ERK2
from the heart or the over-expression of the cytoplasmic ERK specific
phosphatase DUSP6.
and DUSP16. Three cytoplasmic DUSPs: DUSP6, DUSP7, and
DUSP9 were reported to be ERK1/2 specific (Dickinson and
Keyse, 2006), and one inducible nuclear DUSP, the DUSP5,
was shown to be nuclear ERK1/2 specific (Nayak et al., 2014).
However, both DUSP7 and DUSP9 may also be able to inactivate
p38 (Dickinson and Keyse, 2006).
MEK-ERK1/2 Gain of Function
Most of the initial research that investigated ERK1/2 in the
heart aimed at determining the role of ERK1/2 in cardiac
hypertrophy and protection. However, no consensus was achieved
in this regard. Studies conducted on cultured neonatal rat
cardiomyocytes, which represented the majority of the studies
in this field, yielded inconsistent results. Consequently, the use
of transgenic and gene-targeted mice has emerged as a more
consistent and reliable research methodology.
The first reported experiments using transgenic mice for
this application were conducted by Bueno et al. (2000) who
generated transgenic mice over-expressing an activated MEK1
mutant under the transcriptional control of cardiac-specific a-
myosin heavy chain promoter. Histologic and echocardiographic
analysis showed an increase in cardiac wall thickness and
improved cardiac function in these mice, with no signs of cardiac
decompensation or premature death after a follow-up period
of 12 months. It should be noted that overexpression of active
MEK1 not only resulted in increased ERK1/2 phosphorylation,
but also in increased total ERK1/2 protein levels, presumably
through stabilization and reduced degradation of endogenous
ERKs. Moreover, these mice were significantly less affected by
ischemia/reperfusion induced apoptosis compared with wild type
mice (Lips et al., 2004).
To further test the effects of ERK1/2, transgenic mice lines
over-expressing ERK2 in the heart were generated. These mice,
however, showed no alteration in cardiac size or function
compared with wild-type mice indicating that without being
activated, ERK2 overexpression is not enough to induce cardiac
hypertrophy (Bueno and Molkentin, 2002). This conclusion was
supported by results obtained from crossing theMEK1 transgenic
mice and the ERK2 transgenic mice which showed synergistic
hypertrophy. In line with these observations, transgenic mice
over-expressing activated RAS in the heart were generated and
showed cardiac hypertrophy. However, they had an increased
tendency towards cardiac decompensation and dilatation
indicating pathologic response. Activation of additional signaling
pathways other than MEK-ERK1/2, by activated RAS could
possibly explain this phenotype.
Additional studies conducted on transgenic mice tried to
explore alternative, and perhaps more physiologic approaches
in achieving ERK1/2 gain of function in the heart. For
example, Maillet et al. (2008) explored ERK1/2 gain of function
effects on cardiac hypertrophy using Dusp6 null ( = ) mice.
These mice showed mild increase in baseline phosphorylation
of ERK1/2 compared with wild-type mice indicating higher
ERK1/2 baseline activity. However, no increase in the extent
or the duration of ERK1/2 activation was observed following
hypertrophic stimulation, indicating that DUSP6 specifically
regulates basal ERK1/2 level of activity. The Dusp6 ( = )
knockout mice showed significant increase in heart weight
without an increase in cardiomyocyte circumference at baseline.
Histologic analysis of heart tissue from 3-day-old Dusp6  = 
neonates showed a significant increase in the number of
proliferating cells indicated by phospho-histone H3 labeling
and BrdU incorporation. Consequently, the authors concluded
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that the increase in cardiac weight is secondary to increased
proliferation of cardiomyocytes. Since Dusp6 knockout did not
affect stimulus induced ERK1/2 activation, it was not surprising
that stimulus driven hypertrophy using pressure overload or
agonists was not different in the Dusp6 null mice.
Numerous studies in other systems showed that the MEK-
ERK pathway is an important regulator of cell proliferation and
oncogenic transformation, but outside this study, few ERK1/2
gain-of-function or loss-of-functionmodels documented an effect
on cardiomyocyte proliferation. Very recently the role of the
NRG1 co-receptor ERBB2 in cardiomyocyte proliferation was
examined (D’Uva et al., 2015). Constitutively active ca-ERBB2
transgenic mice showed increased cardiomyocyte proliferation
and activation of ERK1/2. The pharmacologic inhibition ofMEK-
ERK1/2 signaling suppressed the cardiomyocyte proliferation,
dedifferentiation, and reduced the hypertrophic response in these
ca-ERBB2 transgenic mice, therefore ERK1/2 signaling may be
required for cardiomyocyte proliferation.
More recently, a new site of phosphorylation on Threonine 188
(Thr 188) in ERK2 was identified by Lorenz et al. (2009) who
introduced an alternative pathway leading to the activation of
ERK2 in the heart. In this study, it was shown that stimulation of
Gq coupled receptors leads to the release of G protein bg subunits
which serves as scaffold for the RAF-MEK-ERK pathway leading
to ERK2 activation; i.e., phosphorylation of the TEY motif, and
subsequent ERK2 dimerization and auto-phosphorylation on Thr
188. Furthermore, ERK2 auto-phosphorylation on Thr188 leads
to the translocation of ERK2 into the nucleus where it can activate
effectors that have been shown to promote cardiac hypertrophy.
To study the in vivo effect of Thr188 auto-phosphorylation, they
generated transgenic mice overexpressing wild-type Erk2 (Erk2
T188T), Erk2 T188A and Erk2 T188S (phosphorylation-deficient
Erks), and Erk2 T188D (gain-of-function Erk). Replacing the
Threonine at position 188 with the negatively charged aspartate
is generally considered to be a phosphomimetic mutation. No
hypertrophy was observed in any of these mice compared to wild-
type mice at baseline, suggesting that over-expression of wildtype
ERK does not lead to hypertrophy, that the phosphorylation
on Thr188 on ERK2 is not sufficient to induce cardiac
hypertrophy, or that the Erk2T188D mutant dose not mimic
the endogenous phosphorylation on Thr188. However, following
pressure overload, mice expressing Erk2T188D displayed more
prominent hypertrophy than those expressing the wild type or the
phosphorylation-deficient ERK2. Furthermore, a follow-up study
by Ruppert et al. (2013) concluded that Thr188 phosphorylation
is associated with the pathologic form of hypertrophy. They
showed that interferencewith this auto-phosphorylation using the
mutant ERK2T188A,which is dominant-negative for ERKThr188
signaling, attenuated cardiomyocyte hypertrophic responses to
phenylephrine and chronic pressure overload in vitro and in vivo,
but did not affect physiological cardiac growth and function
(Ruppert et al., 2013).
In summary, these results support a pro-hypertrophic role for
MEK1-ERK1/2 signaling, and show that a strong and sustained
activation of the cascade is sufficient to cause concentric cardiac
hypertrophy with protection against apoptotic stimuli (Figure 1).
It also appears that specificmode of ERK1/2 activationmay dictate
the hypertrophic response of the heart to various stimuli, and that
not all ERK1/2 activation events are the same, but the specific role
of Thr188 phosphorylation in the heart is not entirely clear.
ERK1/2 Loss of Function
Loss-of-function approaches were used to assess the necessity
of MEK-ERK signaling to cardiac hypertrophy. Due to the
lethality of Erk2 homozygous null mice, initial studies used Erk1
homozygote null and Erk2 heterozygote null Erk1 = ; Erk2+= 
mice. These mice failed to show a significant reduction in cardiac
hypertrophy after pressure overload induced by transverse aortic
constriction (TAC) or after exercise-induced cardiac hypertrophy
with swimming (Purcell et al., 2007). When crossed to transgenic
mice expressing a constitutively active MEK1 transgene, these
mice did display less cardiac hypertrophy, demonstrating that
ERK1/2 are the MEK proteins targets inducing hypertrophy.
Together these results could be taken as evidence that ERK1/2
signaling was not necessary for cardiac hypertrophy, although it
was possible that the remaining ERK2 activity was sufficient to
mediate the required downstream signaling events. The Erk2+= 
heterozygous mice did show significant reductions in fractional
shortening after TAC compared with wildtype mice and Erk1 = 
mice showed a trend toward reduced function, showing that while
ERK1/2 activity may not be necessary for concentric hypertrophy,
it does play a role in the process.
Dual-specificity MAP kinase phosphatases (MKPs) provide
a negative regulatory network on MAPK activation. Of those,
DUSP6 was shown to specifically bind ERK1 and ERK2
in vitro, and this specific binding allows it to specifically
dephosphorylate and inactivate these MAPKs in vivo in the
cytoplasm (Caunt and Keyse, 2013). Several lines of transgenic
mice overexpressing DUSP6 specifically in the heart were
generated, and as expected did not demonstrate evidence for
cardiac ERK1/2 phosphorylation even after stimulation. Similar
to theErk1 =  andErk2+=  nullmice theDUSP6 overexpressing
mice showed the same degree of hypertrophy after TAC pressure
overload or after swimming as wildtype mice (Purcell et al.,
2007). Following long term pressure overload of 14 weeks after
TAC the DUSP6 overexpressing mice did show more cardiac
hypertrophy of the eccentric type with dilation, inflammation,
and reduced function. This model also supported the notion that
ERK1/2 signaling was not necessary for concentric hypertrophy,
but did suggest for the first time that EKR1/2 activity may be
required to prevent eccentric growth in the context of pressure-
overload. It should be noted though, that whileDUSP6 specifically
inactivate ERK1/2 in the cytoplasm, DUSP5 is responsible for
dephosphorylating nuclear ERK. Therefore, it could not be
completely ruled out that some nuclear ERK activity was still
present in DUSP6 transgenic mice hearts.
To more fully understand the necessity of ERK1/2 signaling
for cardiac hypertrophy we generated cardiac specific ERK1/2
targeted mice: Erk1 = ; Erk2 fl/fl and used two different Cre
recombinase lines- the Nkx2.5 knock-in Cre or the a-Myosin
heavy chain transgenic Cre to eliminate both ERK1 and ERK2
from cardiomyocytes in the heart (Kehat et al., 2011). Elimination
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of either ERK1 alone in ERK1 =  mice or the elimination of
cardiac ERK2 alone in ERK2 fl/fl;Cre mice did not result in
a baseline phenotype. However, the elimination of both from
the heart resulted in spontaneous eccentric hypertrophy with
dilatation of the heart and elongation of the cardiomyocytes. As
predicted by Laplace equation the dilation of the heart resulted
in increased diastolic wall stress with eventual reduced function,
further cardiac dilatation and ultimately death. To explore the
mechanism of reduced function in these mice we also studied
the elongated cardiomyocytes after isolation. While the function
of the dilated heart was reduced, the function of the elongated
cardiomyocytes was increased, further demonstrating that the
increase diastolic wall stress was responsible for the reduced
function of the heart.
Cardiomyocytes from cardiac ERK1/2 null mice (Erk1 = ;
Erk2 fl/fl;Cre) displayed spontaneous elongation suggesting that
ERK1/2 signaling is required to inhibit eccentric growth of the
heart. When stressed with stimuli that elicit concentric growth
like angiotensin II and adrenergic phenylephrine administration
these cardiomyocytes responded with growth both in width and
in length. In agreement with other models, these data show that
ERK1/2 signaling may be sufficient but is not required to myocyte
growth in width and concentric growth of the heart. Yet, ERK1/2
signaling is required to prevent myocyte elongation and eccentric
growth both at baseline and during stimuli that usually cause
concentric growth (Figure 1).
Fibrosis with increased collagen accumulation between
myocytes is a structural hallmark of prolonged pressure
overload and concentric hypertrophy, and to a lesser degree
may accompany volume overload (Spinale, 2007). However,
neither the activated MEK1 transgenic mice nor the Erk1 = ;
Erk2 fl/fl;Cre null mice showed any increase in collagen
accumulation even after long term follow up for the former and
with deteriorating function in the latter. This dissociation of
cardiomyocyte growth from the fibrosis that is usually associated
with it suggests that ERK1/2 signaling may be specifically
dedicated to control the structural aspect of the cardiomyocyte
hypertrophy.
Pharmacologic Agents to Study ERK1/2
Loss of Function
ERKs have long been implicated as regulators of cardiac
hypertrophy on account of their activation in response to most,
if not all, stress stimuli known to induce hypertrophic growth.
As a result, intense efforts are underway to develop compounds
that inhibit this pathway and thus provide a potential therapeutic
agent that could attenuate cardiac growth. In addition, numerous
studies in the pathogenesis of cancer are exploring these MEK
inhibitors in attempt to develop therapeutic agents for the
treatment of cancer.
The most studied inhibitors of the MEK1/2-ERK1/2 pathway
are U0126 and PD98056. These inhibitors do not target the ATP
binding pocket of MEK and therefore are relatively MEK specific
(Duncia et al., 1998; English and Cobb, 2002). However, they do
inhibit all MEKs including MEK1, MEK2 and to a lesser extent
MEK5.
Several in vitro studies have explored these MEK inhibitor’s
effects in cultured cardiomyocytes. MEK inhibition using U0126
attenuated contractile dysfunction and abolished the increase in
ANF gene expression induced by endothelin-1 and isoprenaline
(Munzel et al., 2005). U0126 also blocked cardiomyocyte growth
induced by endothelin-1 and phenylephrine (Yue et al., 2000).
Likewise, PD98059 reduced b-type natriuretic promotor activity
induced by endothelin or mechanical strain (Liang et al.,
2000) and reversed leukemia inhibitory factor (LIF)-induced
cardiomyocyte hypertrophy (Kodama et al., 2000). Collectively
these studies support the pro-hypertrophic effects of the MEK-
ERK cascade.
The effects of pharmacologic inhibitors of ERK1/2 have been
demonstrated in vivo as well. It has been shown that the NO
synthase inhibitor (L-NAME) induced myocardial remodeling
was markedly attenuated by oral administration of PD98059 in
Wistar-Kyoto rats (Sanada et al., 2003). Additionally, a study that
explored the effects of the regulator of G protein signaling 5 (Rgs5)
on cardiac remodeling and heart failure showed a protective
role of Rgs5 in the presence of pressure overload which was
attributed to the inhibition of MEK1/2-ERK1/2 pathway (Li et al.,
2010). Indeed, cardiac dilatation and decompensation, induced
by pressure overload, were much more prominent in Rgs5 n 
mice compared with Rsg5+=+ mice and were markedly reversed
when these mice were treated with U0126. Exercise results in
physiologic cardiac hypertrophy, and voluntary running was also
shown to result in activation of the ERK cascade. Treatment with
U0126 in this setting did not prevent the cardiac hypertrophy but
did reduce the cytoplasmic translocation of PPARa (el Azzouzi
et al., 2012). The inhibitory effect on PPARa was shown to be
mediated by MEK1, and not by its downstream effector kinase
ERK1/2 (el Azzouzi et al., 2012). These studies also indicate that
MEK may be necessary for cardiac hypertrophy. However, as
with all other pharmacological approaches, it is very difficult to
completely exclude off-target effects of these drugs, as in particular
some effects on MEK5 have been noted.
ERK1/2 Activation Patterns
The quantitative information about a constant extracellular
stimulus like pressure overload may be carried by the number of
active ERK molecules, or signal amplitude, or by the frequency
with which the activity of ERK shifts between active and inactive
states, or signal frequency (Figure 2). It is also not clear whether
the cell responds to the absolute number of phosphorylated
ERK molecules or to the fraction of phospho-ERK to total
ERK molecules in the cytoplasm or nucleus. For example,
the interpretation of constant epidermal growth factor receptor
signaling in cells was shown to result in discrete pulses of
ERK activation and incorporated both frequency and amplitude
modulated elements (Albeck et al., 2013). A study in human
cancer cells found a very large cell to cell variability in the levels
of nuclear ERK2. Despite this variability, the amount of ERK2
entering the nucleus upon EGF stimulation was proportional
to the basal level of nuclear ERK2 in each cell, suggesting a
fold-change response mechanism (Cohen-Saidon et al., 2009).
Therefore the question whether downstream targets of ERK
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FIGURE 2 | The quantitative information about a constant extracellular
stimulus like pressure overload may be carried by the duration of ERK
activation, by amplitude of ERK activation (phosphorylation level), by
the frequency with which the activity of ERK shifts between active and
inactive states, by the translocation of ERK to a subcellular location
such as the nucleus, or through a combination of these factors.
respond to ERK fold or absolute changes in phospho-ERK
molecules is still open. It should be noted that overexpression of
wild-type ERK in the heart did not result in cardiac hypertrophy
both at baseline or following TAC pressure overload and that
overexpression of constitutively active mutant of MEK1 in the
heart resulted in an increase in both total ERK1/2 and phospho-
ERK1/2. Since a detailed estimation of phospho-ERK to total ERK
ratios in both nucleus and cytoplasm was not performed in these
studies it is difficult to draw direct conclusion from these studies
regarding ERK cellular sensing.
It is also not understood how pressure and volume overload
are interpreted as ERK activity in the heart. Evidence from
cultured cells suggests that ERK activity occurs in bursts of
about 30 min, and strong stimuli cause an increase in pulse
duration and a decrease in the spacing between pulses (Albeck
et al., 2013). Due to this fast kinetic it is virtually impossible
to assess the relationship between pressure or volume overload
and the associated profile of ERK1/2 activation in vivo over time
with current tools. Acutely, most hypertrophic stimuli appear
to activate and induce phosphorylation of ERK1/2 (Kehat and
Molkentin, 2010a). Comparison between TAC pressure overload
model and vena cava fistula volume overload model showed
ERK1/2 activation at 24 h with the former but not with the latter,
hinting at different oscillatory behavior of ERK1/2 activation in
pressure and in volume overload (Lorenz et al., 2009). Genetic
manipulation of ERK1/2 activity in mice hearts allows precise and
robust modulation of the cascade. However, these manipulations
only mimic the extreme ends of the physiologic activity spectrum
where activity is either extremely strong or completely lacking.
Therefore the exact pathophysiological connections between
mechanical overload, patterns of ERK activation, and growth
patterns of the heart are still not clear.
ERK1/2 Targets in Hypertrophy
Several proteins have been suggested as the downstream ERK1/2
targets that mediate hypertrophy. ERK1/2 directly phosphorylate
the transcriptional effectors Elk-1, Ets1, Sap1a, and c-Myc
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(Bueno and Molkentin, 2002). In cultured cardiomyocytes
the phosphorylation of Elk-1 by ERK was shown to be
important for early gene activation following phenylephrine-
induced hypertrophy (Babu et al., 2000), and c-Myc is a driver
of cardiac hypertrophy (Zhong et al., 2006). Mitogen- and stress-
activated protein kinase-1 (MSK1) is another ERK1/2 target
that was implicated in phenylephrine induced cardiomyocyte
hypertrophy (Markou et al., 2004).
The transcription factor GATA4 is an important regulator of
stimuli induced cardiac hypertrophy. Knock-in mice in which
Serine 105 was replaced with alanine in GATA4 failed to
develop cardiac hypertrophy in response to pressure overload
or adrenergic stimulation with phenylephrine, suggesting that
phosphorylation of GATA4 in this position is crucial for GATA4
function (van Berlo et al., 2011). GATA4 can be directly
phosphorylated at Serine 105 by ERK1/2 and p38, and both
ERK1/2 and p38 activity were shown to be necessary for
the increase in GATA4 DNA binding that occurred following
acute wall stretching (Tenhunen et al., 2004). Activated MEK1
transgenic mice failed to develop hypertrophy when crossed
to GATA4 null mice (Gata4 fl/fl; b-Myosin Heavy chain Cre),
showing that GATA4 is required for MEK-ERK1/2 hypetrophic
function.When the activatedMEK1 transgenicmice were crossed
to the GATA4 S105A mutant mice cardiac hypertrophy was
significantly blunted, suggesting that phosphorylation of GATA4
at Serine 105 is required for MEK-ERK1/2 hypetrophic function.
Potential ERK1/2 targets were also assessed in order to
understand the function of Thr188 ERK2 phosphorylation
(Lorenz et al., 2009). The basal level of phosphorylation of
the Erk1/2 targets p90RSK, p70S6K, Elk1, MSK1, and c-Myc
was similar in all Erk2T188-mutant mouse lines examined
suggested that Thr188 phosphorylation is not sufficient to activate
ERK1/2, or that the phosphomimetic mutation did not fully
mimic phosphorylation at Thr188 position. Induction of pressure
overload by TAC also increased the level of phosphorylation of
the cytosolic proteins p90RSK and p70S6K similarly in all the
mice lines. In contrast the phosphorylation levels of the nuclear
Elk1, MSK1, and c-Myc following TAC pressure overload was
higher in the Erk2 T188D phosphomimetic mutant hearts. These
data suggested that Thr188 phosphorylation in combination
with pressure overload stimulation preferentially increased the
phosphorylation of nuclear ERK1/2 targets. It was also suggested
that hypertrophic stimuli induce nuclear ERK1/2 signaling by
suppressing expression of DUSP5 through MEK-ERK1/2 and
class I HDAC-dependent mechanism, and that class I HDAC
inhibition blocks nuclear ERK1/2 activation (Ferguson et al.,
2013). Overexpression of DUSP5 inhibited agonist induced
hypertrophy in cardiomyocytes strengthening the view that
nuclear ERK1/2 activity is important for hypertrophy.
Summary
The many studies described leave little doubt that MEK-ERK1/2
signaling is important for cardiac hypertrophy. Stimuli that
elicit concentric hypertrophy such as pressure overload and Gq
coupled receptor activation result in activation of the cascade
at least acutely, and gain-of-function models showed increased
hypertrophy. In contrast loss-of-function model showed cardiac
dilatation and eccentric hypertrophy. It is also clear that not
all ERK1/2 activation events are the same. Sustained baseline
activation, post-stimulus peak activation or activation amplitude,
the duration or frequency of activation, and the cytoplasmic
versus the nuclear localization of activated ERK all likely play
different roles. Carful dissection of these activation events in
the future may reveal more refined roles for ERK activation and
cardiac hypertrophy.
Acknowledgments
This study was supported by the Rappaport Family Institute for
Research in the Medical Sciences, The Clinical Research Institute
at Rambam, RambamMedical Center, TheMARIE CURIE action
Career Integration Grants, and The Israel Science Foundation and
Israel Ministry of Health.
References
Albeck, J. G., Mills, G. B., and Brugge, J. S. (2013). Frequency-modulated pulses of
ERK activity transmit quantitative proliferation signals. Mol. Cell. 49, 249–261.
doi: 10.1016/j.molcel.2012.11.002
Babu, G. J., Lalli, M. J., Sussman, M. A., Sadoshima, J., and Periasamy, M.
(2000). Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos
gene activation during cardiac myocyte hypertrophy. J. Mol. Cell Cardiol. 32,
1447–1457. doi: 10.1006/jmcc.2000.1185
Bueno, O. F., De Windt, L. J., Tymitz, K. M., Witt, S. A., Kimball, T. R.,
Klevitsky, R., et al. (2000). The MEK1-ERK1/2 signaling pathway promotes
compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341–6350.
doi: 10.1093/emboj/19.23.6341
Bueno, O. F., and Molkentin, J. D. (2002). Involvement of extracellular signal-
regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ. Res. 91,
776–781. doi: 10.1161/01.RES.0000038488.38975.1A
Caunt, C. J., and Keyse, S. M. (2013). Dual-specificity MAP kinase phosphatases
(MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 280, 489–504.
doi: 10.1111/j.1742-4658.2012.08716.x
Chatterjee, S., Bavishi, C., Sardar, P., Agarwal, V., Krishnamoorthy, P., Grodzicki,
T., et al. (2014). Meta-analysis of left ventricular hypertrophy and sustained
arrhythmias.Am. J. Cardiol. 114, 1049–1052. doi: 10.1016/j.amjcard.2014.07.015
Cohen-Saidon, C., Cohen, A. A., Sigal, A., Liron, Y., and Alon, U. (2009).
Dynamics and variability of ERK2 response to EGF in individual
living cells. Mol. Cell. 36, 885–893. doi: 10.1016/j.molcel.2009.11.
025
D’Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho,
S., et al. (2015). ERBB2 triggers mammalian heart regeneration by promoting
cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627–638.
doi: 10.1038/ncb3149
Dickinson, R. J., and Keyse, S. M. (2006). Diverse physiological functions for
dual-specificity MAP kinase phosphatases. J. Cell Sci. 119, 4607–4615. doi:
10.1242/jcs.03266
Duncia, J. V., Santella, J. B. III, Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E.,
et al. (1998). MEK inhibitors: the chemistry and biological activity of U0126, its
analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8, 2839–2844. doi:
10.1016/S0960-894X(98)00522-8
el Azzouzi, H., Leptidis, S., Bourajjaj, M., Van Bilsen, M., Da Costa Martins, P.
A., and De Windt, L. J. (2012). MEK1 inhibits cardiac PPARalpha activity by
direct interaction and prevents its nuclear localization. PLoS ONE 7:e36799. doi:
10.1371/journal.pone.0036799
English, J. M., and Cobb, M. H. (2002). Pharmacological inhibitors of MAPK
pathways. Trends Pharmacol. Sci. 23, 40–45. doi: 10.1016/S0165-6147(00)
01865-4
Frontiers in Pharmacology | www.frontiersin.org July 2015 | Volume 6 | Article 1497
Mutlak and Kehat ERK1/2 and cardiac hypertrophy
Ferguson, B. S., Harrison, B. C., Jeong, M. Y., Reid, B. G., Wempe, M. F., Wagner,
F. F., et al. (2013). Signal-dependent repression of DUSP5 by class I HDACs
controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc. Natl. Acad.
Sci. U.S.A. 110, 9806–9811. doi: 10.1073/pnas.1301509110
Fjeld, C. C., Rice, A. E., Kim, Y., Gee, K. R., and Denu, J. M. (2000). Mechanistic
basis for catalytic activation of mitogen-activated protein kinase phosphatase
3 by extracellular signal-regulated kinase. J. Biol. Chem. 275, 6749–6757. doi:
10.1074/jbc.275.10.6749
Gaasch, W. H., Delorey, D. E., St John Sutton, M. G., and Zile, M. R. (2008).
Patterns of structural and functional remodeling of the left ventricle in
chronic heart failure. Am. J. Cardiol. 102, 459–462. doi: 10.1016/j.amjcard.2008.
03.081
Gaasch, W. H., and Zile, M. R. (2011). Left ventricular structural remodeling in
health and disease: with special emphasis on volume, mass, and geometry. J.
Am. Coll. Cardiol. 58, 1733–1740. doi: 10.1016/j.jacc.2011.07.022
Goktepe, S., Abilez, O. J., Parker, K. K., and Kuhl, E. (2010). A multiscale model
for eccentric and concentric cardiac growth through sarcomerogenesis. J. Theor.
Biol. 265, 433–442. doi: 10.1016/j.jtbi.2010.04.023
Grossman, W., and Paulus, W. J. (2013). Myocardial stress and hypertrophy: a
complex interface between biophysics and cardiac remodeling. J. Clin. Invest.
123, 3701–3703. doi: 10.1172/JCI69830
Kehat, I., Davis, J., Tiburcy, M., Accornero, F., Saba-El-Leil, M. K., Maillet, M., et
al. (2011). Extracellular signal-regulated kinases 1 and 2 regulate the balance
between eccentric and concentric cardiac growth. Circ. Res. 108, 176–183. doi:
10.1161/CIRCRESAHA.110.231514
Kehat, I., and Molkentin, J. D. (2010a). Extracellular signal-regulated kinase 1/2
(ERK1/2) signaling in cardiac hypertrophy. Ann. N. Y. Acad. Sci. 1188, 96–102.
doi: 10.1111/j.1749-6632.2009.05088.x
Kehat, I., and Molkentin, J. D. (2010b). Molecular pathways underlying cardiac
remodeling during pathophysiological stimulation. Circulation 122, 2727–2735.
doi: 10.1161/CIRCULATIONAHA.110.942268
Kodama, H., Fukuda, K., Pan, J., Sano, M., Takahashi, T., Kato, T., et al. (2000).
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in
gp130-mediated cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 279,
H1635–H1644.
La Gerche, A., and Prior, D. L. (2007). Exercise–is it possible to have too
much of a good thing? Heart Lung. Circ. 16(Suppl. 3), S102–S104. doi:
10.1016/j.hlc.2007.03.014
Li, H., He, C., Feng, J., Zhang, Y., Tang, Q., Bian, Z., et al. (2010). Regulator of
G protein signaling 5 protects against cardiac hypertrophy and fibrosis during
biomechanical stress of pressure overload. Proc. Natl. Acad. Sci. U.S.A. 107,
13818–13823. doi: 10.1073/pnas.1008397107
Liang, F., Lu, S., and Gardner, D. G. (2000). Endothelin-dependent and -
independent components of strain-activated brain natriuretic peptide
gene transcription require extracellular signal regulated kinase and
p38 mitogen-activated protein kinase. Hypertension 35, 188–192. doi:
10.1161/01.HYP.35.1.188
Lips, D. J., Bueno, O. F., Wilkins, B. J., Purcell, N. H., Kaiser, R. A.,
Lorenz, J. N., et al. (2004). MEK1-ERK2 signaling pathway protects
myocardium from ischemic injury in vivo. Circulation 109, 1938–1941.
doi: 10.1161/01.CIR.0000127126.73759.23
Lorenz, K., Schmitt, J. P., Schmitteckert, E. M., and Lohse, M. J. (2009). A new
type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat. Med. 15,
75–83. doi: 10.1038/nm.1893
Maillet, M., Purcell, N. H., Sargent, M. A., York, A. J., Bueno, O. F., andMolkentin, J.
D. (2008). DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation
at baseline and increased myocyte proliferation in the heart affecting
disease susceptibility. J. Biol. Chem. 283, 31246–31255. doi: 10.1074/jbc.M80
6085200
Markou, T., Hadzopoulou-Cladaras, M., and Lazou, A. (2004). Phenylephrine
induces activation of CREB in adult rat cardiac myocytes through MSK1
and PKA signaling pathways. J. Mol. Cell Cardiol. 37, 1001–1011. doi:
10.1016/j.yjmcc.2004.08.002
Munzel, F., Muhlhauser, U., Zimmermann, W. H., Didie, M., Schneiderbanger, K.,
Schubert, P., et al. (2005). Endothelin-1 and isoprenaline co-stimulation causes
contractile failure which is partially reversed by MEK inhibition. Cardiovasc.
Res. 68, 464–474. doi: 10.1016/j.cardiores.2005.06.020
Nayak, J., Gastonguay, A. J., Talipov, M. R., Vakeel, P., Span, E. A., Kalous, K. S., et
al. (2014). Protein expression, characterization and activity comparisons of wild
type and mutant DUSP5 proteins. BMC Biochem. 15:27. doi: 10.1186/s12858-
014-0027-0
Purcell, N. H., Wilkins, B. J., York, A., Saba-El-Leil, M. K., Meloche, S., Robbins,
J., et al. (2007). Genetic inhibition of cardiac ERK1/2 promotes stress-
induced apoptosis and heart failure but has no effect on hypertrophy in
vivo. Proc. Natl. Acad. Sci. U.S.A. 104, 14074–14079. doi: 10.1073/pnas.061090
6104
Ruppert, C., Deiss, K., Herrmann, S., Vidal, M., Oezkur, M., Gorski, A., et al. (2013).
Interference with ERK(Thr188) phosphorylation impairs pathological but not
physiological cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 110, 7440–7445.
doi: 10.1073/pnas.1221999110
Sanada, S., Node, K., Minamino, T., Takashima, S., Ogai, A., Asanuma, H.,
et al. (2003). Long-acting Ca2+ blockers prevent myocardial remodeling
induced by chronic NO inhibition in rats. Hypertension 41, 963–967. doi:
10.1161/01.HYP.0000062881.36813.7A
Shaul, Y. D., and Seger, R. (2007). The MEK/ERK cascade: from signaling
specificity to diverse functions. Biochim. Biophys. Acta 1773, 1213–1226. doi:
10.1016/j.bbamcr.2006.10.005
Spinale, F. G. (2007). Myocardial matrix remodeling and the matrix
metalloproteinases: influence on cardiac form and function. Physiol. Rev.
87, 1285–1342. doi: 10.1152/physrev.00012.2007
Tenhunen, O., Sarman, B., Kerkela, R., Szokodi, I., Papp, L., Toth, M., et al.
(2004). Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall
stress-induced activation of GATA-4 binding in adult heart. J. Biol. Chem. 279,
24852–24860. doi: 10.1074/jbc.M314317200
van Berlo, J. H., Elrod, J. W., Aronow, B. J., Pu, W. T., and Molkentin, J. D.
(2011). Serine 105 phosphorylation of transcription factor GATA4 is necessary
for stress-induced cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. U.S.A. 108,
12331–12336. doi: 10.1073/pnas.1104499108
Weeks, K. L., and McMullen, J. R. (2011). The athlete’s heart vs. the failing heart:
can signaling explain the two distinct outcomes? Physiology 26, 97–105. doi:
10.1152/physiol.00043.2010
Wellbrock, C., Karasarides, M., andMarais, R. (2004). The RAF proteins take centre
stage. Nat. Rev. Mol. Cell Biol. 5, 875–885. doi: 10.1038/nrm1498
Yue, T. L., Gu, J. L., Wang, C., Reith, A. D., Lee, J. C., Mirabile, R. C., et al. (2000).
Extracellular signal-regulated kinase plays an essential role in hypertrophic
agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy.
J. Biol. Chem. 275, 37895–37901. doi: 10.1074/jbc.M007037200
Zhong, W., Mao, S., Tobis, S., Angelis, E., Jordan, M. C., Roos, K. P., et al.
(2006). Hypertrophic growth in cardiac myocytes is mediated byMyc through a
Cyclin D2-dependent pathway. EMBO J. 25, 3869–3879. doi: 10.1038/sj.emboj.
7601252
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Mutlak and Kehat. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or
licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org July 2015 | Volume 6 | Article 1498
